Magnolol Reduces Atopic Dermatitis-like Symptoms in BALB/c Mice

• Published in: Life (Basel, Switzerland) Vol. 14; no. 3; p. 339
• Main Authors: Lee, Ju-Hyun, Im, Dong-Soon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: 1-Chloro-2,4-dinitrobenzene; anti-atopy; Asthma; Atopic dermatitis; atopy; Care and treatment; CD4 antigen; Cell differentiation; Cells; Chemokines; Chinese medicine; Complications and side effects; Cytokines; Dermatitis; Diagnosis; Differentiation (biology); Dinitrobenzene; Drug dosages; Edema; Erythema; Foxp3 protein; Helper cells; Herbal medicine; Hyperplasia; Immunoglobulin E; Inflammation; Interleukins; Lesions; Lymph nodes; Lymphatic system; Lymphocytes; Lymphocytes T; magnolia; Magnolia officinalis; magnolol; Medicine, Botanic; Medicine, Herbal; Pathogenesis; Patient outcomes; Peripheral blood; Skin; Skin diseases; Skin lesions; Surveys; T cells; γ-Interferon; South Korea; magnolia; anti-atopy; dermatitis; magnolol; Magnolia officinalis; atopy; atopic dermatitis
• DOI: 10.3390/life14030339
• ISSN: 2075-1729

In traditional Korean medicines, is commonly included for the remedy of atopic dermatitis, and magnolol is a major constituent of . Its pharmacological effects include anti-inflammatory, hepatoprotective, and antioxidant effects. Using BALB/c mice repeatedly exposed to 1-chloro-2,4-dinitrobenzene (DNCB), magnolol was evaluated in atopic dermatitis-like lesions. Administration of magnolol (10 mg/kg, intraperitoneal injection) markedly relieved the skin lesion severity including cracking, edema, erythema, and excoriation, and significantly inhibited the increase in IgE levels in the peripheral blood. A DNCB-induced increase in mast cell accumulation in atopic dermatitis skin lesions was reversed by magnolol administration, as well as a rise in expression levels of pro-inflammatory Th2/Th17/Th1 cytokines' (IL-4, IL-13, IL-17A, IFN-γ, IL-12A, TARC, IL-8, and IL-6) mRNAs in the lymph nodes and skin (n = 5 per group). In lymph nodes, magnolol reversed DNCB's increase in CD4 RORγt Th17 cell fraction and decrease in CD4 FoxP3 regulatory T cell fraction. The results also showed that magnolol suppressed T cell differentiation into Th17 and Th2 cells, but not Th1 cells. Magnolol suppresses atopic dermatitis-like responses in the lymph nodes and skin, suggesting that it may be feasible to use it as a treatment for atopic dermatitis through its suppression of Th2/Th17 differentiation.